Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 79

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 79
---
 on Liminatus if the regulatory environment changes or Liminatus fails to comply with regulatory requirements.

•

Liminatus’s brand and reputation are critical to its success, and any publicity, regardless of accuracy, that portrays Liminatus negatively could adversely impact operating results.

•

The risks and costs to Iris if the Business Combination is not completed, including the risk of diverting management’s focus and resources from other businesses combination opportunities, which could result in Iris being unable to effect a business combination within the completion window, which would require Iris to liquidate.

•

The risk that Iris’s stockholders may object to and challenge the Business Combination and take action that may prevent or delay the closing, including by voting against the Business Combination Proposal.

•

The terms of the Business Combination Agreement provide that Iris will not have any surviving remedies against Liminatus or its equityholders after the closing to recover for losses as a result of any inaccuracies or breaches of Liminatus’s representations, warranties, or covenants set forth in the Business Combination Agreement.

•

The risk that the potential benefits of the Business Combination may not be fully achieved, or may not be achieved within the expected time frame.

<div align='center'>14</div>

TABLE OF CONTENTS

•

The fees and expenses associated with completing the Business Combination will be significant.

•

The potential that a significant number of Iris’s stockholders elect to redeem their shares prior to the consummation of the Business Combination, which would reduce the amount of cash available following the closing.

•

The challenges associated with preparing Liminatus for the applicable disclosure and Nasdaq listing requirements.

•

Liminatus will require additional capital to complete the research and development and potential commercialization of its intellectual property assets. No assurance can be given that such additional capital will be available on terms acceptable to Liminatus, if at all. If Liminatus is unable to raise capital when needed or on acceptable terms, Liminatus could be forced to delay, reduce, or eliminate its planned research and development programs or any future commercialization efforts.

•

The risk that the Transactions might not be consummated or completed in a timely manner or that the closing might not occur despite Iris’s best efforts, including by reason of a failure to obtain the approval of Iris’s stockholders, litigation challenging the Business Combination or that an adverse judgment granting permanent injunctive relief could indefinitely enjoin the consummation of the Business Combination.

•

Continuing coronavirus outbreaks may have a material adverse effect on Liminatus’s business, liquidity, financial